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1.  Introduction 
Structured frameworks for benefit-risk analysis in drug licensing decisions are being implemented 
across a number of regulatory agencies worldwide. The aim of these frameworks is to aid the analysis 
and communication of the benefit-risk assessment throughout the development, evaluation and 
supervision of medicines. In this review, authors from regulatory agencies, pharmaceutical companies 
and academia share their views on the different frameworks and discuss future directions. 
2.  Background 
The balance of benefits and risks is at the heart of drug licensing decisions. According to a review of 
selected European agencies, licensing decisions are made intuitively, the responsibility of an 
accountable senior assessor or of a team, after extensive analysis of the data and discussion among 
experts.(1) The U. S. Food And Drug Administration (FDA) shows a similar role for clinical judgment 
after extensive analysis and discussion.(2) The practice has been to assess overall benefits and risks 
(holistically) using a prevalently intuitive approach (without precise definition of the value structure 
and trade-offs). As regulators in Germany described it, “First start from the benefits (‘Is there a 
clinically significant benefit?’)… if there is a clinically significant benefit…, look at adverse events. Are 
they acceptable for the patient?”.(1)  
Arguably, the robustness of the intuitive decision-making is safeguarded in a number of ways. 
Expertise plays a key role. Regulators typically use written reports and processes, briefings, and 
committee discussions until they are confident that they have determined the best course of action. 
External expert advice may be sought (e.g., through advisory committees) although this may 
sometimes be a challenge as the outside experts may be less familiar with benefit-risk judgements 
than the regulators.(3)  
Regulators have a responsibility to communicate the benefits and risks of medicines in a way that is 
accessible (clear and understandable) to a broad audience to inform treatment decisions and to ensure 
transparency about the reasons and rationales that play a part in decisions. Regulatory agencies have 
published their assessment reports which include a summary of the data submitted and the 
conclusions. Other forms of external communication have included published perspectives or 
outreaching to the medical or patient community (e.g., FDA’s Patient Focus Drug Development 
Initiative). However, accessible communication about the key benefits and risks that underlie the 
decisions as well as value judgments and trade-offs between benefits and risks, is often lacking. While 
detailed benefit-risk assessments are sometimes described in prominent publications, this is the 
exception much more than the rule for regulatory agencies.(4, 5) 
For instance, rimonabant (Acomplia) was authorized in the EU in 2006 for the treatment of obesity and 
withdrawn from the market in 2009. The benefit-risk analysis that led to the European Medicines 
Agency to recommend the withdrawal of the marketing authorization is described as follows: “The 
efficacy of rimonabant as a weight-reducing agent can be considered as moderate. The beneficial 
effects on cardiovascular risk factors may be of limited importance considering the reported short 
duration of use. (...) The expected benefits are considered as more limited compared to what was 
foreseen at the time of approval. (…) The absolute risk of psychiatric adverse event in clinical practice 
may be more common compared to what was seen at the time of approval. (…)”.(6)  
Eichler et al. have pointed out that regulators should consider refining their methods of assessing 
benefit–risk balances and switch from “implicit” to “explicit” decision making — that is, to an approach 
involving explicit descriptions not only of all decision criteria and interpretations of data but also 
valuations, such as the weighting factors for potential treatment outcomes.(7)  
To address some of these methodological and communication aspects of benefit-risk assessment, drug 
regulators, the pharmaceutical industry and academia have acted in synergy to explore a range of 
available approaches  (Figure 1).(8) These range from descriptive textual approaches to decision-
analytic methods that aim to quantitatively express the value judgements and trade-offs.  In any 
approach, the aim is to facilitate the benefit-risk analysis and to better define the decision context, the 
drivers of the decision, and the associated uncertainty. The purpose of this paper is to describe the 
status of benefit-risk initiatives and plans of leading regulatory agencies as to their implementation in 
drug licensing decisions. We also describe two industry initiatives, and an independent approach to an 
overarching framework. We discuss expected changes in the near future, such as the wider 
implementation of structured frameworks and the need for further assessing the usefulness of 
quantitative decision-analysis approaches in the real-life setting.  
3 
 
3.  Proposed Frameworks, Tools and Visualizations 
3.1.  The European Medicines Agency (EMA) implementation of the PrOACT-
URL framework 
The EMA initiatives on benefit-risk methodology go back to 2008, when the need for a more systematic 
and transparent approach was recognized.(9)  
A task force was set up comprising decision theorists, regulators, psychologists and statisticians, under 
the guidance of Lawrence Phillips, Professor of Operational Research at the London School of 
Economics, to identify approaches that would suit the complex organization of EMA (multiple 
committees with experts from several dozen organizations throughout the European Economic Area). 
A stepwise approach was proposed, within a wider framework called PrOACT-URL,(10) which follows 
the eight-stage general decision framework proposed by Keeney et al.(11) In short, the following steps 
are considered: 
• Problem formulation (indication, unmet need, objective of the pivotal clinical trial); 
• Objectives (a full set of criteria covering the favorable and unfavorable effects, e.g., clinical 
efficacy and safety outcomes); 
• Alternatives (treatment options being compared and regulatory options, e.g., approve or reject); 
• Consequences (the magnitudes of all effects and their desirability or severity; this is summarized 
best in an “effects table”); 
• Trade-offs (the judgement about the benefit-risk balance, and the rationale for the judgement; 
this is best done through a multi-criteria decision analysis (MCDA) or similar method); 
• Uncertainty (whatever the source);  
• Risk attitude (consideration that affect attitude to risk, e.g., unmet need, may vary depending 
on stakeholders); 
• Linked decisions (consistency with similar past decisions and impact on future decisions). 
The EMA framework includes a tabular display (“effects table”) of important effects and their 
uncertainty (Table 1). According to feedback collected from EMA’s regulatory network, the table is a 
useful display of the key issues that can improve the transparency of the benefit-risk assessment, and 
support the communication among EMA’s committees and the public.(12) As of 2015, the “effects 
table” forms an integral part of the benefit-risk section of the assessment reports of new drug 
applications and guidance is available for reviewers on how to use the table.(13)  
While quantitative implementation of the PrOACT-URL is possible, i.e., formalizing explicitly the value 
structure,  and the “effects table” provides the key attributes for readily initiating quantitative 
approaches, the version of the PrOACT-URL as applied by the EMA reviewers when assessing benefits 
and risks is mostly a framework that structures the assessment conceptually within the review 
templates, with trade-offs generally being weighed intuitively and described in qualitative terms. 
There is an ongoing debate about pros and cons of decision-analysis approaches at the level of EMA’s 
scientific committees (Table 2). Exploring real-life use of MCDA for EMA’s benefit-risk assessment is 
being considered, particularly for complex situations (e.g., many conflicting benefits and risks, close 
cases, or cases where the data or clinical situation are unusual and a well-established course of action 
is unavailable from experience). The EMA has also been exploring MCDA to elicit value judgments from 
patients to inform the scientific assessment by regulators.(14) 
The EMA does not impose any particular methodology to industry submitting a benefit-risk assessment 
as part of their drug applications. However, the EMA has encouraged applicant companies to include on 
a voluntary basis any decision-analysis approach, if available, to gain more experience with such 
approaches.  
Since February 2015, the main scientific committee for human drugs (Committee for Medicinal 
Products for Human Use) started including the “effects table” in its assessment reports for new drug 
applications. The EMA is currently working on the wider implementation of the current framework 
across procedures and committees, including the development of further guidance for reviewers, and 
exploring opportunities for implementing additional tools, including methods described in the 
Innovative Medicines Initiative PROTECT project.(15) In terms of future directions, the EMA is 
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exploring approaches to facilitate participation of patients and consumers in benefit-risk evaluation, 
including suitable approaches on how to capture patients’ values and preferences. 
3.2.  U.S. FDA Structured Approach to Benefit-Risk Assessment in Drug 
Regulatory Decision-Making 
Over the past several years, FDA has developed a structured approach to benefit-risk assessment in 
regulatory decision-making for human drug and biologic products. 
The FDA Benefit-Risk Assessment Framework was developed through extensive review and analysis of 
previous and ongoing regulatory decisions. In 2013-2017, FDA made certain commitments to carry this 
work forward as part of the reauthorization of the Prescription Drug User Fee Act (PDUFA).  These 
commitments include further development and implementation of the framework into FDA’s human 
drug and biologic review process. Section 905 of the FDA Safety and Innovation Act of 2012 also 
requires FDA to implement structured benefit-risk assessment in the agency’s new drug review 
process. 
The FDA’s Benefit-Risk Framework considers the following dimensions as part of the benefit-risk 
assessment: Analysis of Condition; Current Treatment Options; Benefit; Risk; and Risk Management. 
The first two dimensions, Analysis of Condition and Current Treatment Options, represent the 
framework’s therapeutic area considerations and are distinct from the other drug-specific dimensions 
in the framework. The therapeutic area information represents the current state of knowledge of the 
condition and an assessment of the available therapies for the patient population.  Both dimensions 
represent critical elements for establishing the context in which a regulatory decision is made, an 
important aspect of FDA’s decisions. As knowledge and understanding of the disease improve, or as 
new therapies are developed, this information can be updated to establish a new context for future 
regulatory decisions in the therapeutic area. 
The additional dimensions of Benefit, Risk, and Risk Management represent the product-specific area of 
the framework. The information found here relates specifically to the drug under review. As knowledge 
of a drug’s benefits and risks changes post-approval, this information can be updated in the 
framework, reflecting the dynamic nature of the benefit-risk assessment during a drug’s lifecycle. 
Within each of these dimensions, reviewers note the relevant important evidence and uncertainties 
based on the current state of knowledge, relevant available information, and their review of the data.  
Guided questions within each dimension of the framework prompt reviewers to consider important  
information that could impact their assessments.  Reviewers are then asked to draw conclusions within 
each dimension, noting important implications for the regulatory decision. 
Finally, the information within each of the framework dimensions is integrated and distilled into the 
Benefit-Risk Summary and Assessment, a succinct well-reasoned text-based analysis that explains 
FDA’s rationale for the regulatory decision, including important clinical judgments that contributed to 
the decision and the benefit-risk trade-offs that are an inherent part of regulatory decision-making.  
The assessment draws on the key supporting evidence and uncertainties, accounts for the 
understanding of the condition, and considers the available therapies that establish the context in 
which benefits and risks are weighed. It also includes the rationale to support the product labelling and 
other necessary risk management as well as post-marketing requirements/commitments if more 
information is necessary to further characterize the benefits or risks of the drug.  
 
During the agency’s development of the framework, FDA recognized that a critical element of widely 
adopting a structured approach to benefit-risk assessment was integration into existing work processes 
and products.  In March 2015, FDA began using a newly revised template for clinical reviews that 
incorporates the Benefit-Risk Framework as part of the executive summary of the review.  This 
template is currently being used for new molecular entity new drug applications (NME NDAs) and 
original biologics license applications (BLAs), as part of a staged implementation plan.  An incremental 
implementation plan allows opportunity for continued refinement of the framework and its integration 
into the human drug review process before further expansion into additional types of applications. As 
the benefit-risk assessment is revisited in the post-market setting based on new information for these 
applications, review teams analyzing the safety issue will be expected to update the benefit-risk 
framework with the analysis conducted, including any regulatory action resulting from that work, as 
appropriate.  
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3.3.  The Japanese PMDA Points to Be Considered by the Review Staff 
Involved in the Evaluation Process of New Drug 
Currently, the benefit-risk “framework” for the assessment of marketing authorization applications for 
new drugs follows the “Points to Be Considered by the Review Staff Involved in the Evaluation Process 
of New Drug” in 2008.(16) This document uses a check-list approach and summarizes the points that 
need to be considered during the actual assessment process of new medical products (Figure 2).  The 
points concerning benefit-risk include the following: 
• Has the efficacy been clearly confirmed? 
• Have factors related to the recognized risk been clearly identified? 
• Has any effective treatment been identified to prevent/inhibit occurrence of the recognized risk? 
• Is the recognized risk acceptable, even if it is serious, when considering the benefits? 
The regulatory decisions on each consideration points are described in the review report. 
In the post-authorization stage a re-examination system plays an important role.  A new medicinal 
product containing a new active ingredient is re-examined 8 years after approval as new product.  All 
the collected post-marketing data are assessed on the basis of benefit-risk balance to reconfirm the 
clinical effectiveness of the drug.  The assessment report of re-examination is published.  
Furthermore, for important issues regarding efficacy or safety and regulatory actions taken in the 
post-approval stage, PMDA publishes the assessment report even earlier than 8 years post-approval.  
The research group on the Japanese Risk Management Plan (J-RMP) was established in April 2012 
supported by the Ministry of Health, Labour and Welfare research fund to explore implementation of 
effective RMP in Japan.  Researchers from academia, industry and regulators from PMDA participate in 
this group and the study projects include how to assess benefit-risk in line with J-RMP. J-RMP 
guidance came into force in April 2013.(17)  In J-RMP, the benefit-risk assessment is required at 
selected milestones.  RMPs are continuously updated and additional actions are taken as necessary. 
The research group is now discussing the methods of benefit-risk assessment.  In 2015, future 
directions about what should be done in Japan for the improvement of benefit-risk assessment will be 
suggested by the research group.   
3.4.  International regulators initiatives and the Centre for Innovation in 
Regulatory Science (CIRS) Universal Methodology for Benefit Risk 
Assessment (UMBRA)  
Since its inception in 2001, the CIRS has been actively involved in investigating ways that companies, 
regulatory agencies, and other stakeholders approach the analysis and consequent decisions about the 
benefits and risks of medicines.   
Regulatory initiatives in Australia, Canada, Singapore and Switzerland: The 
Consortium on Benefit-Risk Assessment (COBRA) and further collaborations 
The Consortium on Benefit-Risk Assessment represents a group of like-minded regulators representing 
Australia, Canada, Singapore and Switzerland, who believe that they can each improve their efficiency 
by leveraging efforts towards similar goals.  Since 2008, a series of projects was started, aiming to 
allow these regulators to exchange review reports and use these reports in their own. One of those 
projects was the development of a benefit risk assessment template (“COBRA Benefit Risk Template”).  
CIRS worked closely, over a period of 5 years, with these agencies to conceptualize, refine and pilot a 
standardized descriptive methodology approach.(8, 18)  The approach was originally based on the EMA 
guidance document of 2008 (19) and has evolved since to comply with the UMBRA framework (see 
below).(20)   
Following the experience with the COBRA Benefit Risk Template, members of the consortium have 
continued to collaborate on inclusion of a benefit risk section in their assessment templates.  In 
general, members currently favor a qualitative approach to the description of benefits and risks, and 
do not include any specific visualization techniques in their templates.  As benefit-risk assessment 
evolves, this may change. The current project on benefit risk envisages the agencies having a common 
section on benefit risk assessment in their respective assessment report templates within 2015.  
Following this, the agencies intend to evaluate possibilities for a common public assessment report 
template.  
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The initial incentive for development of a common benefit risk assessment template was to facilitate 
sharing these assessment reports among the agencies.  The ability of regulators to share assessment 
reports depends on factors including their respective legal frameworks, availability of a suitable 
electronic system, and the ability to use these reports as part of their decision frameworks. Issues 
related to efficient sharing of assessment reports are being addressed in a variety of multinational fora 
including the International Consortium of Medicines Regulatory Agencies (ICMRA), the International 
Generic Drug Regulators Pilot (IGDRP), among others.   
Regulatory initiatives in Chinese Taipei, China, Indonesia, Malaysia, Singapore and 
Philippines 
A number of regulatory agencies are working with CIRS to pilot a summary version of the COBRA 
Benefit Risk Template as one aspect of their quality decision making processes. This CIRS initiative 
(international Summary Approach to Benefit Risk Evaluation, iSABRE), is based on the recognition that 
integrating a standardized approach to benefit-risk assessment into the regulatory review process is 
not only a facilitator of good review practices, but encourages an overarching approach to quality 
decision making. CIRS has completed an initial pilot and this has been evaluated by Chinese Taipei, 
China, Indonesia, Malaysia, Singapore and Philippines and is under consideration for evaluation by 
Saudi Arabia (SFDA) and South Africa.  These agencies are characterized by their use of different 
review models and these pilot studies will help to determine the generalizability of the iSABRE 
approach in a broader context of drug development and assessment. 
The CIRS UMBRA 
The UMBRA was developed by CIRS based on the realization that a high degree of consistency has 
been observed across the frameworks developed by regulators and industry, with each sharing eight 
common elements: a decision context; the ability to build a value tree;  refining the value tree; 
assessing the relative importance of each benefit and risk; evaluating and scoring against other 
treatment options; evaluating uncertainty around the information; the concise presentation of results- 
with the option of using visualizations; and ultimately, applying expert judgment to make and 
communicate the outcome.(20)  
The common elements of UMBRA can be applied to the development of any number of assessment 
tools, each providing a consistent and transparent approach to the appraisal of medicines during 
development, regulatory review and post-approval surveillance.  For example, the EMA, FDA, and the 
Benefit-risk Action Team (BRAT) frameworks can each be mapped to the specific elements of the 
UMBRA framework.  CIRS has been advocating the BRAT process in constructing the benefit-risk 
section of the Common Technical Document used by companies when submitting drug applications to 
regulatory authorities, with UMBRA serving as the common framework upon which the benefit-risk 
section of the submission can be built. CIRS advocates that all new tools and processes developed to 
assess and communicate the benefits and risk of medicines should map to UMBRA to ensure a common 
regulatory language for the systematic, structured approach to benefit risk assessment.  
 
3.5.  The Pharmaceutical Research Manufacturers of America (PhRMA) 
BRAT Framework 
The BRAT Framework was co-developed by PhRMA and several PhRMA member companies and traces 
its origins to 2005, when PhRMA proposed a project to review regulatory approaches to benefit-risk 
assessment, with an eye to recommending a transparent, systematic approach useful to structuring 
and facilitating benefit-risk decision-making.  Informed by principles of decision science, the BRAT 
Framework is guided by a number of precepts: a systematic approach to defining the decision context 
and outcomes, documentation of underlying assumptions, transparency of summarization measures, 
the flexibility to accommodate differing technical benefit-risk methodologies and perspectives, and the 
use of visual displays to communicate complex data.  The resulting BRAT Framework is best 
characterized as a general platform for benefit-risk assessment that facilitates the selection, 
organization, summarization, and interpretation of evidence relevant to benefit-risk decisions.   
 
Since its inception, the BRAT Framework has been iteratively developed and tested, first by the BRAT 
in conjunction with member PhRMA companies, in which the framework was tested using hypothetical 
drugs and simulated scenarios that encompassed the challenges and realities typically encountered in 
pharmaceutical development and benefit-risk assessment.(21, 22) In this setting, the framework was 
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effective in facilitating benefit-risk decision making.  Subsequently, a voluntary pilot program was 
conducted among PhRMA members to evaluate the framework's real-world utility, flexibility, and value. 
Upon conclusion of the pilot program, in which multiple companies applied the BRAT Framework to 
products of their choice, pilot program participants unanimously found the framework to be effective 
and flexible, with applicability to a broad range of circumstances.(23)  Beyond the pilot, the framework 
has also been used independently by BRAT members and others in various applications and public 
meetings, including FDA Advisory Committee meetings and periodic benefit-risk evaluation 
reports.(24-27) 
The BRAT framework formally consists of the six steps in Table 3, though it has been modified and 
extended by individual companies that have implemented custom versions of BRAT.  These steps and 
the BRAT documentation are highly focused on medical treatments, though they are based on 
principles found in general decision analysis approaches.  The framework applies to both development 
and post-approval assessments and can be used by both sponsors and health authorities.   
Particular novel highlights of the BRAT Framework include  
• Documenting the rationale for all key components of the decision, such as the decision to include 
or exclude particular endpoints.  This documentation is particularly valuable for the current ICH 
and EMA requirements for Periodic Benefit-risk Evaluation Reports (PBRERs), which require 
explicitly specifying those benefits and risks considered key to the assessment. 
• Allowing for multiple versions of a value tree of key endpoints needed for the assessment 
depending on data availability, the identified vs. potential nature of the endpoints, and the level of 
detail needed for the audience. 
• Customizing the framework, to account for the differences between what would ideally be used in a 
benefit-risk assessment and what information is measurable and available.  This step is particularly 
critical in post-approval assessment, where data are collected from multiple sources with different 
endpoints and varying levels of quality. 
• Tabular and graphic displays that clearly depict difference between treatments in all benefits and 
harms included in the value tree.  Key benefit-risk summary tables summarize the treatment 
effects and potential risk differences or other measures for all benefits and harms in one table 
(Figure 3).  These tables are similar to the “effects table” used in PrOACT-URL.  Risk difference 
forest plots summarize large amounts of information on treatment differences for multiple benefits 
and harms (Figure 4).  These displays support rapid interpretation of information on multiple 
outcomes.(21) 
• While no particular means of weighting endpoints is proscribed in the BRAT framework, the value 
tree and key benefit-risk summary table provide the requirements for readily initiating quantitative 
approaches. 
The software released with the BRAT Framework allows for creation of value trees, key benefit-risk 
summary tables with graphic annotations, and risk difference or relative risk forest plots.  The current 
tool supports dichotomous endpoints only. 
Several companies have implemented their own version of BRAT, borrowing ideas from the original 
BRAT work and extending it with their existing processes or requirements.  The BRAT software is in 
use, though several companies have developed their own versions with additional capabilities. 
In 2012, the BRAT Framework was transitioned to the CIRS (see section 3.4). The BRAT 
documentation and software are available at the CIRS site (www.cirs-brat.org).  
3.6.  The World Self-Medication Industry tools for the Benefit-Risk 
Assessment of Nonprescription Drugs (BRAND tools) 
The availability of nonprescription drugs is an important component of efficient healthcare delivery as it 
facilitates appropriate self-management by consumers and thus improves the utilization of traditional 
healthcare resources.  The principles of benefit-risk assessment for nonprescription drugs are the same 
as for prescription drugs.  However, their proper application requires explicit incorporation of the 
unique context in which nonprescription drug decisions are made.  For example, the regulatory 
consideration will often be whether a specific drug should have nonprescription vs prescription 
marketing authorization.  Further, this evaluation will often be conducted after the drug has had 
prescription marketing authorization for some period of time.  In this case the benefit-risk assessment 
is based on the incremental benefits and incremental risks that differentiate prescription and 
nonprescription use of the drug.  This incremental benefit-risk will be driven by how consumers behave 
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when deciding to use the drug and over the course of therapy (Table 4).  These behaviors are 
influenced by labelling of the nonprescription product and perhaps pharmacists input.  Specifically, 
while use of nonprescription drugs under a collaborative care model between consumer and pharmacist 
is encouraged, the drugs are often used without the assessment and instructions of a healthcare 
professional prescriber. 
In consideration of the above, the World Self-Medication Industry contracted with outside experts (Eric 
P. Brass, Ragnar Lofstedt and Ortwin Renn) to develop benefit-risk tools optimized for regulatory 
decision making involving nonprescription drugs.   The resulting Benefit-Risk Assessment for 
Nonprescription Drugs (BRAND) tools have been published(28, 29) and seen application in a variety of 
settings.  The tools begin with a value-tree(21, 22, 30) modified to include common benefit-risk 
domains for nonprescription drugs in order to comprehensively identify all benefit and risk attributes 
which have the potential to contribute to the drug’s net benefit-risk.(28)  This value-tree is designed to 
be completed early in development and facilitate alignment amongst all stakeholders, including 
regulators.  An evaluation matrix is then applied to each attribute which independently assessed the 
frequency at which the attribute is likely to occur in the nonprescription setting and the clinical 
consequences of the event should it occur.(29)  In this way commonly occurring attributes that have 
no clinical sequelae can be differentiated from attributes likely to contribute to incremental benefit or 
risk.  This evaluation matrix should be completed early in development to identify critical data gaps 
that contribute uncertainty to the assessment and must be addressed during the development 
program.   At the conclusion of the development program the evaluation matrix is again completed to 
provide a final overall benefit-risk profile.(29)   To ensure the longitudinal application of the tools, and 
to maximize communication and transparency, it is recommended that an integrative approach such as 
the International Risk Governance Council framework(31) be utilized.(28)  The BRAND tools are 
intended to be flexible and non-proscriptive to accommodate varied cultures and statutes in different 
regulatory jurisdictions. 
Since their introduction the principles underlying the BRAND tools have seen wide acceptance and been 
applied implicitly or explicitly in sponsor-regulator discussions, communications and submissions.   For 
example, both the United Kingdom’s Medicines and Healthcare products Regulatory Agency  and the 
New Zealand Medicines and Medical Devices Safety Authority have incorporated aspects of the BRAND 
tools into their guidance on classification of medicines.(32, 33)  Importantly, sponsors have used the 
tools in internal exercises to better understand the needs of nonprescription development programs 
prior to initiating programs and to aid in early communications with regulators. 
Of note, while the above discussion focuses on the evaluation of switching a drug from prescription to 
nonprescription status, the BRAND tools apply equally well to the post-approval assessment of an 
existing nonprescription drug.  Indeed, the components of the BRAND tools may also be useful in the 
assessment of some prescription drugs or medical devices as the underlying principles of longitudinal 
application, emphasis on communication and transparency, comprehensive attribute identification, and 
evaluation that reflects both frequency and clinical impact are highly generalizable. 
The future utility of the BRAND tools will likely be dependent on sponsors investing the time in rigorous 
application of the value-tree and scoring matrix tools to characterize drugs under evaluation.  Use of 
the tools to present the benefit-risk assessment will force data-driven annotation of entries, increasing 
acceptance by regulators and other stakeholders.  Further, experience will make clear that the scoring 
matrix is not an absolute quantitative plus/minus summary, but rather a tool for providing an overall 
profile and highlighting the major drivers of benefit-risk.  For example in a recent exercise, application 
of the BRAND tools to nonprescription diclofenac identified an increased rate of cardiovascular events 
as a major potential risk and guided the development of a potential risk mitigation strategy to reduce 
the frequency score in the scoring matrix.(34) 
4.  Discussion 
The structured frameworks that are being implemented at various regulatory agencies reflect common 
objectives, namely to guide the analysis and communication of benefits, risks and trade-offs for 
medicin 
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al products. If adhered to, the frameworks can help setting internal standards and consistency for 
decision-making, enhancing the clarity of the decision-making process, encouraging the use of 
appropriate documentation and a systematic articulation of each benefit and risk and their relative 
importance, providing consistency of communication and visualization of benefits and risks to various 
stakeholders. This is expected to increase transparency and to facilitate the benefit-risk assessment 
process. Structured frameworks might also help increasing alignment between sponsors and regulators 
around critical data elements needed. 
Tables and figures can be used when communicating benefits and risks to a variety of audiences with a 
minimum statistical and medical background. Additional visualizations that may enhance 
communication of benefits and risks for some audiences include network graphs, forest plots, interval 
plots.(35) The frameworks promote a deconstructed approach and encourage analytic thinking, or 
visual approaches that may facilitate intuitive thinking, or a combination of the two as in the CIRS-
BRAT framework.  
With practice, more detailed, possibly even disease-specific, frameworks could be explored. Similar to   
defining objectives and endpoints in clinical trials, more specific frameworks describing the criteria that 
are important to assess benefits and risks in a particular setting could be developed. The tools 
developed for nonprescription medicines described above are an example of a more specific decision 
framework that has been gaining regulatory acceptance.(28, 32)  
Currently, no single framework has been agreed among all regulators. However, in view of the many 
similarities, further harmonization is possible, as reported by CIRS, the Innovative Medicines Initiative 
PROTECT project 2012 and others.(8, 35-37) Harmonization may also affect the way applicant 
companies structure their benefit-risk assessment in regulatory submissions. To this end, an 
International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use Expert Working Group is currently evaluating and revising its guidance 
and documentation for benefit-risk assessment within the Common Technical Document, M4E(R1) 
(Section 2.5.6). The revision is expected to include greater specificity on the format and structure of 
benefit-risk information with the goal of harmonizing the presentation of this information in regulatory 
submissions. Revised guidance is expected by the end of 2016. Again, although currently no single 
framework or decision-analysis method is likely to be accepted by all regulators, it is likely that with 
further experience, additional guidance and best practices will become available. 
One of the challenges for any framework aiming to describe the benefit risk assessment is the 
expression of value trade-offs.  EMA recommends reviewers to describe the importance of different 
effects (a qualitative description of how much the reviewers value the effects, expressing “value 
judgements”) and to compare the effects among each other. The guidance recommends describing 
what the minimally clinically relevant effect worth detecting is, and then comparing the observed 
results against that threshold. For example,   “Generally, given the poor prognosis in terms of survival 
in the context of this advanced cancer setting, an improvement in median overall survival in the order 
of 2-3 months is considered of clinical relevance. The 6 month difference in median overall survival 
observed was considered to be very important from a clinical point of view”. A similar approach can be 
used to describe risks and trade-offs, defining what are acceptable and tolerable risks.(38) Similarly, 
FDA recommends that reviewers clearly communicate the relative importance of the issues and how 
they were weighed in the decision.   The approaches described in the BRAND tools use a semi-
quantitative rating of the importance to illustrate the contribution of each attribute.(29)  Once the 
different effects are ranked according to their importance, value trade-offs can be described along the 
hierarchy of effects by stating what would be the maximum loss  that one is willing to accept in order 
to improve likelihood of achieving a gain on the next most important effect. Further, this may guide 
risk mitigation strategies and prioritize any post-marketing assessments. However, even using these 
approaches, analysis and communication of the value structure and trade-offs remains inherently 
difficult in complex situations, e.g. there are multiple conflicting attributes with no clearly outstanding 
effects, where the benefit-risk assessment requires deep reflection. 
Quantitative decision-analysis approaches such as MCDA that incorporate explicit preference 
information and trade-offs have been explored within structured frameworks as aids to decision-
making as well as communication.(35, 39-44) A number of case studies using MCDA implementations, 
including stochastic multi-criteria acceptability analysis (SMAA) and value theory for the benefit-risk 
assessment of rimonabant, telithromycin, efalizumab, natalizumab and warfarin have been recently 
published.(15, 40) Preferences studies can yield numeric weights that can also augment any of the 
descriptive frameworks. Currently, however, regulators are still debating the usefulness of such 
methods in making or communicating values and decisions in the regulatory context. More experience 
is needed in order to determine the real value of quantitative decision-analytic methods in the 
regulatory setting.  
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Finally, an outstanding question today is to what extent structured frameworks have a positive real 
world impact on benefit-risk decision-making and communication. Although a number of favorable 
impacts are expected in terms of aiding the assessment and its communication, and the initial 
feedback from regulators that have implemented structured frameworks is encouraging, it is probably 
too early for any firm conclusions, as the implementation of these approaches in the regulatory setting 
is still ongoing. For all the frameworks proposed, it is clear that the different stakeholders need more 
experience. Sponsors must invest additional time to explore different approaches in the context of 
regulatory submissions as no single framework or method is likely to be accepted in its current form by 
all regulators.  Likewise, regulators acknowledge that using a structured approach requires additional 
time to complete, but there is recognition that a structured approach is generally a better way to 
communicate a regulatory decision.  As regulators continue with implementation, they will learn what 
features work best in their jurisdictions and within their established procedures in an iterative process. 
Lastly, all stakeholders should continue to engage with each other and explore opportunities for further 
optimization and harmonization of structured approaches to benefit-risk assessment.  
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 Abbreviations:  
PhRMA BRAT: Pharmaceutical Research and Manufacturers of America Benefit-Risk Action Team;  
CIRS, Centre for Innovation in Regulatory Science;  
UMBRA, Unified Methodology for Benefit-Risk Assessment;  
CASS Taskforce of representatives from Health Canada, Australia’s Therapeutic Goods Administration, 
Swissmedic and the Singapore Health Science Authority;  
COBRA, Consortium on Benefit-Risk Assessment;  
SABRE, Southeast Asia Benefit Risk Evaluation; 
EMA, European Medicines Agency;  
US FDA, United States Food and Drug Administration; 
WSMI BRAND, World Self-Medication Industry Benefit-Risk Assessment for Nonprescription Drugs; 
IMI PROTECT WP5, Innovative Medicine Initiative “Pharmacoepidemiological Research on Outcomes of 
Therapeutics by a European ConsorTium”, work package 5; 
Advance, “Accelerated development of vaccine benefit-risk collaboration in Europe”. 
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Figures and tables  
 
Figure 1: Summary of main benefit-risk initiatives  (Modified from M. Ouwens et al., 
ESFPI/PSI Benefit-Risk Special Interest Group meeting 2013.) 
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Figure 2. Schematic representation of the Japanese PMDA Points to Be Considered by the Review Staff Involved in the Evaluation Process 1 
of New Drug.(16)2 
3 
Figure 3: Key benefit-risk summary table for statins for congestive heart failure example of 
the BRAT framework. 
 
 
 
 
 
 
 
 
 
 
Figure 4: Risk difference forest plot for triptans for migraine example.(21) 
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Table 1. Hypothetical example of an “effects table” for lixisenatide for treatment of type 2 diabetes 
mellitus (the data in this example are based on the European Public assessment report 
EMEA/H/C/002445 available on the EMA website www.ema.europa.eu) 
Effect Description U LIX PBO EXE Uncertainties/ 
Strength of 
evidence  
References 
Favourable Effects   
HbA1c Mean change in 
HbA1c from 
baseline  
% -0.79 (1) 
(-0.95, -0.63) 
-0.19 (1) 
(-0.43, 0.05)  
 Effect of LIX more 
pronounced in 
Asian v. Caucasian 
patients (large 
placebo effect 
especially in some 
geographical 
regions).  
(1) Study EFC6018 
-0.83 (2) 
(-0.91,  -0.75)  
 -0.39 (2) 
(-0.51,  -0.28) 
 (2) EFC6014 and 
EFC10743 
-0.79 (3) 
(-0.89,  -0.68) 
 -0.96 (3) 
(-1.06, -
0.86) 
(3) EFC6019 
-0.82 (4) 
(-0.91,  -0.73)  
 -0.10 (4) 
(-0.24, 0.04) 
 (4) EFC6015 
Body weight Mean change in 
body weight 
from baseline 
kg -1.94 (1) 
(-2.40, -1.48) 
-1.98 (1) 
(-2.65,  -1.31) 
  (1) 
-2.12 (3) 
(-2.42,  -1.82) 
 -1.64 (2) 
(-2.07,  -1.20) 
 (2), (3) 
-2.19 (3) 
(-2.47,  -1.91) 
 -3.98 (3)  
(-4.43, -
3.53) 
(3) 
-2.87 (4) 
(-3.26,  -2.48)  
-0.93 (4) 
(-1.39,  -0.47)  
 (4) 
Unfavourable Effects   
Nausea Incidence of 
nausea 
% 26.9 (5) 7.3 (5)  70-80% of the 
patients 
experiencing 
nausea and/or 
vomiting 
completed the 
treatment. 
(5) Pooled data from 
all phase 2/3 
controlled studies 
Vomiting Incidence of 
vomiting 
% 11.4 (5) 2.7 (5)  (5) 
Diarrhoea Incidence of 
diarrhoea 
% 11.1 (5) 8.0 (5)   (5) 
Hypo-glycaemia  Incidence of 
hypo-glycaemia 
% 1.7 (1) 1.6 (1)  Hypo-glycaemia is 
mainly seen when 
LIX treatment is 
combined with 
sulfonylurea. 
(1) 
7.0 (2) 4.8 (2)  (2) 
2.5 (3)  7.9 (3) (3) 
22.7 (4) 15.2 (4)  (4) 
ISRs Incidence of 
ISRs 
% 5.3 (5) 1.9 (5)   (5) 
Allergic 
reactions 
Incidence of 
allergic reactions  
% 0.4 (5) <0.1 (5)   (5) 
Palpitations Incidence of 
palpitations 
% 1.5 (5) 0.7 (5)  CV events between 
LIX and PBO HR 
1.25, 95% C.I.: 
0.67-2.35 
(5) 
Abbreviations: 
U: unit; LIX: lixisenatide; PBO: placebo; EXE: exenatide; HbA1c: glycosylated haemoglobin; ISRs: 
injection site reactions. 
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Table 2. Quantitative frameworks: Commonly held views in favour and against 
Against In favour 
Require more effort than the implicit holistic 
approach. 
Require additional training. 
Some extra effort is needed, at least initially, to 
structure the model. Updating of models is very 
efficient. 
Minimal training necessary. 
 
They do not reflect the mental processes, which 
are prevalently intuitive. 
Intuition can lead to error and bias, particularly 
for inexperienced assessors. 
Implicit mental processes are difficult to 
communicate. 
They are highly subjective. No more subjective than any other decision-
making strategy; but the subjectivity is handled 
explicitly. 
They give a false sense of precision. Weights and outputs from the model have to be 
considered critically, alongside uncertainties. 
They are a “black box” that may obscure the 
expert judgment. 
The methods are relatively straightforward and 
can be easily understood. 
The structure of the model (options, outcomes, 
consequences, objectives and criteria) and all 
quantitative inputs (utilities, probabilities and 
criterion weights) are made explicit. 
High precision is unattainable in the regulatory 
setting. 
Uncertainty can be managed explicitly by 
exploring different weights and assumptions. 
They oversimplify the complexity of the data 
structure and decision context into a “single 
number”. 
The methods are used to explore the interaction 
of many components in the decision.  
A single number summary is an abuse of the 
model.   
Results can be characterized probabilistically 
with the contributions of different components 
displayed.  
The benefit-risk balance is often self-evident 
from the data. Complex quantitative 
frameworks are unnecessary. 
No need to use in self-evident cases. Still, 
decision-making may not be self-evident to all 
stakeholders.   
Whose values? The authority of the decision-
makers will be questioned. 
The impact of different inputs (e.g., from 
patients) can be explored.  
Regulator’s decisions can be scrutinised. 
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Table 3. Steps in the BRAT Framework 
 
Step Description 
1. Define the decision 
context 
Define drug, dose, formulation, indication, patient population, 
comparator(s), time horizon for outcomes, perspective of the decision-
makers (regulator, sponsor, patient, or physician).  
2. Identify outcomes  Select all important outcomes and create the initial value tree. Define a 
preliminary set of outcome measures/endpoints for each. Document 
rationale for outcomes included/excluded. 
3. Identify and extract 
source data  
Determine and document all data sources (e.g., clinical trials, 
observational studies). 
Extract all relevant data into the data source table, including detailed 
references and any annotations to help the subsequent interpretations. 
4. Customize the 
framework  
Modify the value tree based on further review of the data and clinical 
expertise. Refine the outcome measures/endpoints. May include tuning 
of outcomes not considered relevant to a particular benefit-risk 
assessment or that vary in relevance by stakeholder groups.  
5. Assess outcome    
importance  
Apply or assess any ranking or weighting of outcome importance to 
decision-makers or other stakeholders. 
6. Display and interpret key 
benefit-risk metrics  
 
Summarize source data into tabular and graphical displays to aid 
interpretation.  
Challenge summary metrics, review source data, identify and fill any 
information gaps. 
Interpret summary information.  
 
 
 
Table 4. Examples of important behaviours and decisions by consumer when using a nonprescription 
drug which impact benefit-risk.  The consumer will make these decisions based on the drug’s label, 
potentially augmented by a pharmacist, as well as their own knowledge and self-assessment of their 
condition. See the World Self-Medication Industry tools for the Benefit-Risk Assessment of 
Nonprescription Drugs (BRAND tools) 
 
 
  
Does the consumer’s current clinical condition match the indication for the drug? 
Does the consumer have any contraindications for use of the drug? 
Does the consumer have any symptoms or other medical history which require consultation with a 
physician prior to using the drug? 
Is the consumer taking any other drugs for which there is a drug interaction warning with the drug? 
Will the consumer take the drug at the proper dose, at the correct time interval and for the 
appropriate duration of treatment? 
Will the consumer discontinue use of the drug if adverse effects develop? 
Will the consumer seek medical attention if their clinical condition evolves so that self-management 
is no longer appropriate? 
 
 
 
 
